Expert Interview
Discussing KOMET-001 Phase 1b/2 study of Ziftomenib monotherapy in NPM1-mutant R/R AML presented at the ASCO Conference.
Ticker(s): KURAInstitution: Yale University
- Director of the Leukemia and Myeloid Malignancy Program at Yale Cancer Center, Firm Chief of the Duffy Hematology Firm at Yale-New Haven Hospital and an Assistant Professor of Medicine (Medical Oncology and Hematology) at Yale University School of Medicine
- Received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where I also served as chief medical resident
- Received his medical degree from Hannover Medical School in Hannover, Germany and completed residency training at Yale School of Medicine where I also served as chief medical resident
- Received the ASCO Conquer Cancer Foundation Young Investigator Award, the ASH HONORS Award, the Leukemia & Lymphoma Society Translational Research Program Award and several ASH Abstract Achievement Awards
- Manages 500 patients with acute myeloid Leukemia
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Jun 06, 2025
- Call Time
- 03:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
